NCT03315507View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 20, 2017

Primary Completion Date

August 8, 2019

Study Completion Date

August 8, 2019

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

PB1046 Subcutaneous Injection

Eight weekly doses of PB1046.

Trial Locations (2)

15212

Allegheny General Hospital, Pittsburgh

43210

The Ohio State University Wexner Medical Center, Columbus

Sponsors
All Listed Sponsors
lead

PhaseBio Pharmaceuticals Inc.

INDUSTRY